MedDataX Logo

Field Administration of Stroke Therapy-Blood Pressure Lowering

NCT ID: NCT01811693

Last Updated: 2020-10-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2013-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients. The primary objective of the study is to evaluate the feasibility, safety, and physiologic efficacy of field-initiated glyceryl trinitrate in achieving modest reduction of blood pressure. Patients with acute stroke will be identified in the field by paramedics who have received training in basic and advanced cardiac life support, stroke recognition, and specific procedures relevant to the proposed study. Physician-investigators will obtain informed consent for each subject for study entry after cellular phone contact with paramedics. Paramedics will initiate antihypertensive treatment by applying transdermal GTN patch in the first two dose-tiers, and administering a single sublingual GTN metered spray followed by application of the transdermal system in the last dose tier. The sites involved in the study will be emergency medical services rescue ambulances and 8 receiving Stroke Center hospitals in Orange County, California, USA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is technically effective in modestly lowering blood pressure, and is optimal to advance to a pivotal trial. The study design is an open-label dose escalation study with three dose tiers,. It is anticipated that the trial will identify the most promising prehospital GTN regimen to advance to a pivotal, placebo-controlled, phase 3 trial.

Primary Hypothesis: Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation by ED arrival.

The primary study endpoint to test this hypothesis will be the mean change in SBP from pre-treatment to ED arrival.

Secondary Hypotheses:

1. Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation at early post-arrival timepoints and increases the proportion of patients with target blood pressure at ED arrival and early post-arrival timepoints.

The secondary study endpoints analyzed to test these hypotheses will be: 1) mean change in SBP from pre-treatment to 30 minutes after ED arrival and 60 minutes after ED arrival; and 2) the proportion of patients with SBP \< 180 mm Hg at ED arrival, 30, and 60 minutes after arrival.
2. Prehospital initiation of glyceryl trinitrate in the first 2 hours for severely hypertensive patients with stroke is feasible and safe.

Safety of GTN in the first 2 hours for severely hypertensive stroke patients will be assessed by analysis of serious adverse events, neurologic change, and mortality. We hypothesize that initiation of treatment of the patients in the field will be associated with a favorable side effect profile and without severe blood pressure lowering to les than 120 mm Hg systolic.

Successful completion of the study will demonstrate feasibility to recruit hypertensive stroke participants and initiate GTN therapy in the field by paramedics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Hemorrhage Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Tier 1

Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal

Group Type EXPERIMENTAL

Glycerly Trinitrate

Intervention Type DRUG

5mg/24hour (0.2mg/hour) transdermal

Dose Tier 2

Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal

Group Type EXPERIMENTAL

Glycerly Trinitrate

Intervention Type DRUG

10mg/24hour (0.4mg/hour) transdermal

Dose Tier 3

Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN

Group Type EXPERIMENTAL

Glycerly Trinitrate

Intervention Type DRUG

10mg/24hour (0.4mg/hour) transdermal

Glycerly Trinitrate

Intervention Type DRUG

0.4 mg sublingual single metered spray

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycerly Trinitrate

5mg/24hour (0.2mg/hour) transdermal

Intervention Type DRUG

Glycerly Trinitrate

10mg/24hour (0.4mg/hour) transdermal

Intervention Type DRUG

Glycerly Trinitrate

0.4 mg sublingual single metered spray

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nitroglycerine GTN Nitroglycerine GTN Nitroglycerine GTN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Suspected stroke identified with Los Angeles Prehospital Stroke Screen
2. Age 40-80, inclusive
3. Last known well time within 2 hours of treatment initiation
4. Deficit present for \> 15 minutes
5. Systolic blood pressure ≥180

Exclusion Criteria

1. Coma
2. Rapidly improving neurologic deficit
3. Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound the neurological or functional outcome evaluations
4. Severe respiratory distress (O2 sat \< 90% or respiratory rate \< 12 or \> 24)
5. Major head trauma in the last 24 hours
6. Recent stroke within prior 30 days
7. Use of erectile dysfunction therapies in the previous 12 hours
8. Use of type V phosphodiesterase inhibitors
9. Patient unable to give informed consent and no available legally authorized representative (LAR) to provide informed consent
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Los Angeles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeffrey L. Saver

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Los Alamitos Medical Center

Los Alamitos, California, United States

Site Status

FAST-MAG Clinical Trial Coordinating Center

Los Angeles, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FBP001

Identifier Type: -

Identifier Source: org_study_id